| 发明名称 | Crystal modifications of elobixibat | ||
| 摘要 | The present invention relates to crystal modifications of N-{(2R)-2-[({[3,3-dibutyl-7-(methyl-thio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl]oxy}acetyl)amino]-2-phenylethanolyl}glycine (elobixibat), more specifically crystal modifications I, IV, MeOH-1, EtOH-1, 1-PrOH-1 and 2-PrOH-1. The invention also relates to a process for the preparation of these crystal modifications and to a pharmaceutical composition comprising crystal modification IV. | ||
| 申请公布号 | US9409875(B2) | 申请公布日期 | 2016.08.09 |
| 申请号 | US201514920080 | 申请日期 | 2015.10.22 |
| 申请人 | Elobix AB | 发明人 | Bohlin Martin;Tjerneld Erica;Vestermark Andreas;Ymen Ingvar |
| 分类号 | C07D281/10;C07D281/02 | 主分类号 | C07D281/10 |
| 代理机构 | Fish & Richardson P.C. | 代理人 | Fish & Richardson P.C. |
| 主权项 | 1. Crystal modification IV of elobixibat, having an XRPD pattern, obtained with CuKα1-radiation, with peaks at °2θ positions 6.3±0.2 and 19.4±0.2. | ||
| 地址 | Gothenburg SE | ||